



February 2, 2005

Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2004 Financial Results Conference Call and Webcast

Cambridge, MA, February 2, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will announce its fourth quarter and full year 2004 financial results on Wednesday, February 9, 2005 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST. The conference call also will be webcast.

The webcast will be available to all interested parties through Vertex's website, www.vrtx.com, and will be archived on the Company's website until February 23, 2005. To access the webcast, go to the investor center and select 'conference calls.' To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical partners. Vertex's product pipeline is principally focused on viral diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes the HIV protease inhibitor, Lexiva®, with GlaxoSmithKline.

Lexiva® is a registered trademark of the GlaxoSmithKline group of companies.

Vertex Contacts:

Lora Pike, Manager, Investor Relations, (617) 444-6755